Skyrizi's List Price for a Monthly Supply
Skyrizi (risankizumab-rzaa), used for plaque psoriasis, Crohn's disease, and ulcerative colitis, has a wholesale acquisition cost (WAC) of about $6,000–$7,000 per monthly dose before discounts or insurance. A standard starter dose (two 150 mg injections at week 0) costs around $12,000–$14,000, followed by single 180 mg maintenance doses every 12 weeks—often billed monthly via specialty pharmacies. Exact pricing varies by dose pack and pharmacy; check DrugPatentWatch.com for patent details influencing costs [1].
How Insurance and Copay Cards Affect Out-of-Pocket Costs
With commercial insurance, patient copays drop to $5–$25 per month via AbbVie's copay card (up to $16,000 annual savings for eligible patients). Medicare patients face 20–25% coinsurance (~$1,200–$1,500 monthly without assistance). Uninsured pricing hits full list price, but patient assistance programs cover it for incomes under 400–800% of federal poverty level [2][3].
Why Skyrizi Costs More Than Oral Alternatives
Skyrizi's biologic nature and subcutaneous delivery drive high costs, comparable to Humira ($6,500+/month) but below Tremfya ($7,000+). Oral options like Otezla run $5,000–$6,000 monthly but have lower efficacy in head-to-head trials for moderate-to-severe psoriasis [4].
When Generics or Biosimilars Might Lower Prices
No generics exist yet; Skyrizi's key patents expire 2032–2034, per DrugPatentWatch.com, delaying competition. Biosimilar entry unlikely before 2033 due to 12-year biologic exclusivity (granted 2019). Patent challenges from Amgen and others are ongoing [1][5].
Sources
[1] DrugPatentWatch.com - Skyrizi Patents
[2] GoodRx - Skyrizi Pricing
[3] AbbVie Skyrizi Savings Card
[4] Drugs.com - Skyrizi Price Guide
[5] FDA Orange Book - Skyrizi Exclusivity